4-chloro-N-phenylpyridin-2-amine | 1088907-66-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-N-phenylpyridin-2-amine
• CAS: 1088907-66-7
• 化学式: C₁₁H₉ClN₂
• 分子量: 204.659
• InChiKey: VGSCRDGQNWWIRH-UHFFFAOYSA-N

物化性质

• 沸点：
  316.6±27.0 °C(Predicted)
• 密度：
  1.273±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氨甲基吡啶 、 4-chloro-N-phenylpyridin-2-amine 在 (R)-1-[(Sp)-2-(dicyclohexylphosphino)ferrocenyl]ethyldi-tert-butylphosphine 、 palladium diacetate 、 sodium t-butanolate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 0.5h， 以59%的产率得到2-N-phenyl-4-N-(pyridin-3-ylmethyl)pyridine-2,4-diamine
  参考文献：
  名称：

  Selective palladium-catalysed amination of 4-chloropyridines with benzylamines using the Josiphos ligand

  摘要：

  A synthetic strategy for the synthesis of a library of 4-N-benzylamino-2-N-phenyl-pyridines is herein described. The approach involves a Pd-assisted cross-coupling of a 4-chloro-N-phenylpyridin-2-amine intermediate with a range of benzylamines. A variety of ligands were screened, the most successful being the Josiphos ligand, which gave the desired products in good to moderate yields. The reactions occur quickly, within 30 mm, with full conversion of the intermediate into the desired product. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2014.09.115
• 作为产物：
  描述：

  2,4-二氯吡啶 、 苯胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 1.0h， 生成 4-chloro-N-phenylpyridin-2-amine
  参考文献：
  名称：

  Identification of G protein-coupled receptor 120-selective agonists derived from PPARγ agonists

  摘要：

  A weak, nonselective G protein-coupled receptor 120 (GPR120) agonist 10 was found by screening a series of carboxylic acids derived from the peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist 3. Modification based on the homology model of GPR120 led to the first GPR120-selective agonist 12. These results provide a basis for constructing new tools for probing the biology of GPR120 and for developing new candidate therapeutic agents.

  DOI：

  10.1021/jm800970b

文献信息

• Highly Regioselective Palladium-Catalyzed C2-Amination of 2,4-Dichloropyridines: Scope and Limitations
  作者：Rémy Morgentin、Christian Delvare、Patrice Koza

  DOI：10.1055/s-0030-1260080

  日期：2011.8

  The use of palladium(0) enables a highly regioselective C-2 amination of 4,6-dichloronicotinonitrile. Coupling with aminoarenes that are N-acetyl-masked to limit cross-coupling overreaction, leads to 4-chloro-6-anilino nicotinonitrile compounds after deprotection in situ. The scope of these original conditions was evaluated.

  使用零价钯催化剂实现了对4,6-二氯烟腈的高度区域选择性的C-2胺化反应。通过与N-乙酰化保护的氨基芳烃进行偶联，以限制交叉偶联过度反应，然后在原位脱保护后得到4-氯-6-苯胺烟腈化合物。这些原始反应条件的适用范围得到了评估。
• Copper anchored on phosphorus g-C₃N₄ as a highly efficient photocatalyst for the synthesis of <i>N</i>-arylpyridin-2-amines
  作者：Jia-Qi Di、Mo Zhang、Yu-Xuan Chen、Jin-Xin Wang、Shan-Shan Geng、Jia-Qi Tang、Zhan-Hui Zhang

  DOI：10.1039/d0gc03400b

  日期：——

  A copper modified phosphorus doped g-C₃N₄ (Cu/P-CN) has been prepared and identified as an efficient catalyst for the synthesis of N-arylpyridin-2-amine derivatives by the reaction of 2-aminopyridine and aryl boronic acid under the irradiation of blue light.

  一种经过铜改性的磷掺杂的g-C3N4（Cu/P-CN）已经制备并确定为一种高效催化剂，可用于在蓝光照射下通过2-氨基吡啶和芳基硼酸的反应合成N-芳基吡啶-2-胺衍生物。
• PROSTACYCLIN RECEPTOR AGONIST
  申请人：Medshine Discovery Inc.

  公开号：EP3750879A1

  公开（公告）日：2020-12-16

  A compound represented by formula (I) or an isomer or a pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGI2 receptor.

  由化学式（I）表示的化合物或其异构体或其药用可接受的盐。本发明还涉及将其用于制备用于治疗与PGI2受体相关的疾病的药物的应用。
• 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME
  申请人：Japan Tobacco Inc.

  公开号：EP0970954A1

  公开（公告）日：2000-01-12

  3-piperidyl-4-oxoquinazoline derivatives are provided, which is represented by the formula (I): wherein R represents an amino group or a cyclic amino group such as dibenzoazepine, each of which is substituted with a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, or the like, n is an integer of 1 to 4, R3 and R4 independently represents a hydrogen atom, a lower alkyl group, or the like, or a pharmaceutically acceptable salt thereof. Compounds (I) of the present invention have excellent MTP-inhibitory activity. Thus, these compounds not only inhibit formation of LDL that is a cause of arteriosclerotic diseases but also regulate TG, cholesterol, and lipoproteins such as LDL in the blood and regulate cellular lipids through regulation of MTP activity. They can also be used as a new type of preventive or therapeutic agents for hyperlipemia or arteriosclerotic diseases. Furthermore, they can be used as therapeutic or preventive agents for pancreatitis, obesity, hypercholesterolemia, and hypertriglyceridemia.

  提供了3-哌啶基-4-氧代喹唑啉衍生物，由式(I)表示： 其中 R 代表氨基或环状氨基，如二苯并氮杂卓，它们各自被取代或未被取代的芳基、取代或未被取代的杂芳基或类似基团取代，n 是 1 至 4 的整数，R3 和 R4 独立地代表氢原子、低级烷基或类似基团，或其药学上可接受的盐。本发明的化合物（I）具有优异的 MTP 抑制活性。因此，这些化合物不仅能抑制导致动脉硬化疾病的低密度脂蛋白的形成，还能调节血液中的总胆固醇、胆固醇和脂蛋白（如低密度脂蛋白），并通过调节 MTP 活性来调节细胞脂质。它们还可用作高脂血症或动脉硬化疾病的新型预防或治疗药物。此外，它们还可用作胰腺炎、肥胖症、高胆固醇血症和高甘油三酯血症的治疗或预防药物。
• [EN] PROSTACYCLIN RECEPTOR AGONIST<br/>[FR] AGONISTE DU RÉCEPTEUR DE LA PROSTACYCLINE<br/>[ZH] 前列环素受体受体激动剂
  申请人：MEDSHINE DISCOVERY INC

  公开号：WO2019154363A1

  公开（公告）日：2019-08-15

  式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐，并涉及其在制备治疗与PGI 2受体相关疾病药物中的应用。